The Zhitong Finance App learned that Pfizer (PFE.US) stopped developing Danuglipron, an oral diet drug that has received much attention. Investors are betting that this setback may stimulate Pfizer to seek mergers and acquisitions. Shares of several biotech companies developing diet pills rose on Monday. Viking Therapeutics (VKTX.US) rose nearly 11%, GPCR.US (GPCR.US) rose about 19%, Terns Pharmaceuticals (TERN.US) rose 8%, and Metsera (MTSR.US) surged about 30%.

Zhitongcaijing · 04/15 07:09
The Zhitong Finance App learned that Pfizer (PFE.US) stopped developing Danuglipron, an oral diet drug that has received much attention. Investors are betting that this setback may stimulate Pfizer to seek mergers and acquisitions. Shares of several biotech companies developing diet pills rose on Monday. Viking Therapeutics (VKTX.US) rose nearly 11%, GPCR.US (GPCR.US) rose about 19%, Terns Pharmaceuticals (TERN.US) rose 8%, and Metsera (MTSR.US) surged about 30%.